Practical Guide,is a medication that is used to treat both type 2 diabetes and weight loss

The question of does Pfizer make semaglutide is a common one, particularly as semaglutide has become a widely recognized name in the treatment of type 2 diabetes and, more recently, for weight management, weight loss. While Pfizer is a major pharmaceutical company with a significant presence in various therapeutic areas, including metabolic diseases, it is Novo Nordisk that currently manufactures and markets semaglutide under the brand names Ozempic (for diabetes) and Wegovy (for weight loss). Rybelsus is another semaglutide-based product, an oral form for diabetes, also from Novo Nordisk.

However, Pfizer has been actively involved in the development of its own GLP-1 receptor agonist (GLP-1 RA) medications, aiming to compete in the burgeoning market for weight loss drugs. The company has pursued both oral and injectable formulations. One prominent investigational drug from Pfizer is danuglipron, which was discovered and developed in-house at Pfizer. Danuglipron is a type of investigational medicine known as a GLP-1 receptor agonist, designed to mimic the effects of hormones like semaglutide.

Initially, Pfizer was developing danuglipron as a twice-daily oral obesity drug. However, in a significant development, Pfizer announced in April 2025 that it was ending the development of its potential once-daily pill treatment for obesity, danuglipron, after signs of liver injury were observed in a trial participant. This decision followed earlier setbacks, including halting the development of a twice-daily oral obesity drug in December 2023 due to disappointing trial results. These moves represent a setback for Pfizer's plans to compete with pharmaceutical giants like Eli Lilly and Novo Nordisk in the lucrative obesity market.

Despite discontinuing danuglipron, Pfizer has indicated that it is moving forward with another weight-loss pill candidate. The company has selected a preferred once-daily modified-release formulation for its weight loss candidate, signaling continued investment in oral GLP-1 RA therapies. This new candidate aims to offer an alternative to injectable treatments like Wegovy. Pfizer's efforts in this space highlight the intense competition and rapid innovation occurring within the GLP-1 drug class.

It's also worth noting that Pfizer has been exploring other avenues within the GLP-1 landscape. In February 2026, Pfizer picked up the rights to commercialize a recently approved GLP-1 in China, further demonstrating its strategic interest in this therapeutic area as its broader obesity ambitions take shape.

While the direct answer to does Pfizer make semaglutide is no, the company is a significant player in the development of similar GLP-1-based medications. Their journey with danuglipron and other oral candidates underscores the complexities and challenges in bringing these innovative treatments to market, particularly concerning safety and efficacy compared to established injectables like semaglutide. The pharmaceutical industry's pursuit of effective weight loss solutions continues, with companies like Pfizer and Novo Nordisk at the forefront of research and development. For individuals seeking treatments for type 2 diabetes or weight loss, understanding which company produces which medication is crucial for informed decision-making. Semaglutide is a medication that is used to treat both type 2 diabetes and weight loss, and its availability through Novo Nordisk as Ozempic, Wegovy, and Rybelsus remains a key point of reference. Pfizer's ongoing research, even with the discontinuation of danuglipron, suggests they are committed to finding viable solutions in this evolving field.